Umbralisib (UKONIQ) was approved by FDA in February 2021 for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL).
It is an orally available kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon. Umbralisib targeting the delta isoform of PI3K with nanomolar potency and several-fold selectivity over the alpha, beta, and gamma isoforms of PI3K.
This drug contains 1H-pyrazolo[3,4-d]pyrimidine moiety in its backbone.
We have made a set of Building Blocks, that contains such parts – the perfect start for your research!